BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2094 related articles for article (PubMed ID: 17823233)

  • 1. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
    Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
    Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
    Nakagomi-Hagihara R; Nakai D; Kawai K; Yoshigae Y; Tokui T; Abe T; Ikeda T
    Drug Metab Dispos; 2006 May; 34(5):862-9. PubMed ID: 16501004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
    Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of Sutherlandia frutescens for herb-drug interaction.
    Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
    Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans.
    Ishiguro N; Maeda K; Kishimoto W; Saito A; Harada A; Ebner T; Roth W; Igarashi T; Sugiyama Y
    Drug Metab Dispos; 2006 Jul; 34(7):1109-15. PubMed ID: 16611857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.
    Kalgutkar AS; Feng B; Nguyen HT; Frederick KS; Campbell SD; Hatch HL; Bi YA; Kazolias DC; Davidson RE; Mireles RJ; Duignan DB; Choo EF; Zhao SX
    Drug Metab Dispos; 2007 Nov; 35(11):2111-8. PubMed ID: 17686907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide.
    Ishiguro N; Maeda K; Saito A; Kishimoto W; Matsushima S; Ebner T; Roth W; Igarashi T; Sugiyama Y
    Drug Metab Dispos; 2008 Apr; 36(4):796-805. PubMed ID: 18180273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of triple-transfected cells [organic anion-transporting polypeptide (OATP) 1B1/multidrug resistance-associated protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for analysis of the sinusoidal function of MRP3 and MRP4.
    Hirouchi M; Kusuhara H; Onuki R; Ogilvie BW; Parkinson A; Sugiyama Y
    Drug Metab Dispos; 2009 Oct; 37(10):2103-11. PubMed ID: 19628752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
    Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
    PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers.
    Liu L; Cui Y; Chung AY; Shitara Y; Sugiyama Y; Keppler D; Pang KS
    J Pharmacol Exp Ther; 2006 Jul; 318(1):395-402. PubMed ID: 16627748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters.
    Han YH; Busler D; Hong Y; Tian Y; Chen C; Rodrigues AD
    Drug Metab Dispos; 2010 Jul; 38(7):1072-82. PubMed ID: 20360302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.
    Kunze A; Huwyler J; Camenisch G; Poller B
    Drug Metab Dispos; 2014 Sep; 42(9):1514-21. PubMed ID: 24989890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
    Weiss J; Sauer A; Divac N; Herzog M; Schwedhelm E; Böger RH; Haefeli WE; Benndorf RA
    Biopharm Drug Dispos; 2010 Mar; 31(2-3):150-61. PubMed ID: 20222053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
    Kitamura S; Maeda K; Wang Y; Sugiyama Y
    Drug Metab Dispos; 2008 Oct; 36(10):2014-23. PubMed ID: 18617601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of hepatic drug transporter activity and expression by organochlorine pesticides.
    Bucher S; Le Vee M; Jouan E; Fardel O
    J Biochem Mol Toxicol; 2014 Mar; 28(3):119-28. PubMed ID: 24464585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin.
    Hirano M; Maeda K; Matsushima S; Nozaki Y; Kusuhara H; Sugiyama Y
    Mol Pharmacol; 2005 Sep; 68(3):800-7. PubMed ID: 15955871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1.
    Qi X; Wagenaar E; Xu W; Huang K; Schinkel AH
    Toxicol Appl Pharmacol; 2017 Aug; 329():18-25. PubMed ID: 28532671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells.
    Ulvestad M; Nordell P; Asplund A; Rehnström M; Jacobsson S; Holmgren G; Davidson L; Brolén G; Edsbagge J; Björquist P; Küppers-Munther B; Andersson TB
    Biochem Pharmacol; 2013 Sep; 86(5):691-702. PubMed ID: 23856292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 105.